GlaxoSmithKline (CAI:BIOC) Other Current Receivables: E£218 Mil (As of Sep. 2016)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is GlaxoSmithKline Other Current Receivables?

GlaxoSmithKline CAI:BIOC -20.00% Other Current Receivables is E£218 Mil as of Sep. 2016.

GlaxoSmithKline's Other Current Receivables for the quarter that ended in Sep. 2016 was E£218 Mil.

GlaxoSmithKline's quarterly Other Current Receivables increased from Mar. 2016 (E£194.96 Mil) to Jun. 2016 (E£210.14 Mil) and increased from Jun. 2016 (E£210.14 Mil) to Sep. 2016 (E£217.94 Mil).

GlaxoSmithKline's annual Other Current Receivables declined from Dec. 2013 (E£231.37 Mil) to Dec. 2014 (E£175.00 Mil) and declined from Dec. 2014 (E£175.00 Mil) to Dec. 2015 (E£172.27 Mil).

GlaxoSmithKline Other Current Receivables Related Terms

GlaxoSmithKline Other Current Receivables Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Other Current Receivables Chart

GlaxoSmithKline Annual Data
Trend Dec12 Dec13 Dec14 Dec15
Other Current Receivables
306.48 231.37 175.00 172.27

GlaxoSmithKline Quarterly Data
Dec12 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 178.04 172.27 194.96 210.14 217.94

GlaxoSmithKline Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of E£218 Mil mean?
GlaxoSmithKline (CAI:BIOC) has a Other Current Receivables of E£218 Mil as of Sep. 2016. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on GlaxoSmithKline and its competitors.
Is GlaxoSmithKline's Other Current Receivables too high?
GlaxoSmithKline's current Other Current Receivables is E£218 Mil.
How does GlaxoSmithKline's Other Current Receivables compare to PRPH?
GlaxoSmithKline's Other Current Receivables of E£218 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on GlaxoSmithKline and its competitors. GlaxoSmithKline's current Other Current Receivables is E£218 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline stock overvalued right now?
GlaxoSmithKline (CAI:BIOC) has a current Other Current Receivables of E£218 Mil. The current Other Current Receivables is E£218 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For GlaxoSmithKline (CAI:BIOC), the current Other Current Receivables is E£218 Mil as of Sep. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GlaxoSmithKline Business Description

Address Boomerang Building, No 46, Block (J) First Section City Centre, Town Centre, Second floor, Fifth District - New Cairo, Cairo, EGY, 11835
GlaxoSmithKline is a pharmaceutical company. It is focused on developing new medicines in respiratory, HIV, oncology, and immune-inflation. The company is segmented into Commercial Operations and Total Research and development. It generates the majority of its revenue from the Commercial Operations segment.